From R&D to Commercialization: Tackling the Challenges of ODF Process Scale-Up

Oral dissolvable films (ODFs) have emerged as an innovative dosage form, but moving from lab-scale R&D to commercial-scale production requires overcoming significant hurdles. Ensuring process consistency and data comparability across each stage is one of the biggest challenges for regulatory approval and market entry.

Why Is Process Scale-Up So Challenging?

• Equipment differences: Lab models and commercial-scale machines vary greatly, making data hard to compare.
• Parameter inconsistency: Coating thickness, drying conditions, and cutting methods may differ between systems.
• Regulatory requirements: Drug registration demands proof of process continuity and stability; gaps can lead to revalidation or even failure.

Common Industry Pain Points

• Repeated validation: Lab-scale data is often not accepted, forcing revalidation at pilot and commercial stages.
• Increased cost and timelines: Repeated trials extend development cycles and raise costs.
• Process risks: Film quality may become unstable after scale-up, resulting in batch rejections.

HUANGHAI’s Solutions

• Consistent process design: Whether using the MJ150-L or MJ150, the coating and drying logic remains the same, ensuring data comparability.
• Pilot-scale bridge: The MJ150-L acts as a pilot unit, creating a smooth transition between lab research and full-scale production.
• Modular scalability: With modular upgrades, companies can quickly move from R&D to commercial output without starting over.
• End-stage integration: The MJF180 cutting & packaging machine ensures accurate dosing and stable packaging for compliant ODF products.

Compliance and Quality Value

• Improves data continuity to support drug registration and GMP audits.
• Reduces risk from process discrepancies.
• Accelerates time-to-market, increasing commercialization success rates.

Recommended Equipment

• MJ150-L Pilot/Research Coating Machine
• MJ150 Commercial Coating Machine
• MJF180 ODF Cutting & Packaging Machine

Conclusion

ODF process scale-up is more than just expanding capacity — it is about maintaining consistency, compliance, and product stability. With unified process design and modular production lines, HUANGHAI helps clients transition smoothly from R&D to commercialization, minimizing risks and accelerating market entry.

*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.

---

Frequently Asked Questions

Q: What is the difference between an ODF film and a transdermal patch?

A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.

Q: What production output can I expect from a Huanghai ODF machine?

A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.

Q: What drying technology does Huanghai use for ODF production?

A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.

Q: What are the GMP requirements for ODF production equipment?

A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.

For a full overview of the certifications and compliance standards our equipment meets, see our Certifications & Compliance page.

Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?

A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.